Spark Therapeutics Inc (ONCE_old)

NASDAQ
113.57
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    113.47 - 113.90

ONCE_old Overview

Prev. Close
110.75
Day's Range
113.47-113.9
Revenue
35.95M
Open
113.85
52 wk Range
0-0
EPS
-6.55
Volume
0
Market Cap
4.38B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,107,280
P/E Ratio
-
Beta
2.02
1-Year Change
0%
Shares Outstanding
38,523,294
Next Earnings Date
-
What is your sentiment on Spark Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Spark Therapeutics Inc News

Spark Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellBuyBuyStrong Buy
Technical IndicatorsStrong SellStrong SellBuyBuy
SummaryStrong SellNeutralBuyStrong Buy

Spark Therapeutics Inc Company Profile

Spark Therapeutics Inc Company Profile

Employees
368

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company’s gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company’s preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B; and NeuExCell Therapeutics Inc. to develop a novel gene therapy for Huntington's disease. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania. As of December 16, 2019, Spark Therapeutics, Inc. operates as a subsidiary of Roche Holding AG.

Read More
  • The best doctor/researchers at one of the best East Coast Research Hospitals.
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.